Parnell Appoints Tony G Hartnell AM to Board of Directors
Appointment adds an eminent corporate governance expert to the Board as a new Independent Director
SYDNEY, January 4, 2018 (Newswire.com) - Parnell Pharmaceuticals Holdings Ltd (OTC: PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced the appointment of Anthony G Hartnell AM to its Board of Directors.
“We are indeed fortunate to be able to welcome Tony Hartnell AM to our Board. His acceptance of a directorship secures us an exceptional Independent Director with impeccable credentials in business success, enterprise financing and good governance, and unique expertise in corporate law and regulation,” said Dr. Alan Bell, Chairman of Parnell. “Mr. Hartnell brings a wealth of knowledge and experience to our Board, having chaired five publicly listed companies including BT Global Asset Management Ltd, Television & Media Services Ltd and Chiquita Brands South Pacific Ltd.
“His distinguished career also included his service as the Inaugural Chairman of the Australian Securities Commission and Chairman of the National Companies and Securities Commission. Under the national Honours system, Mr. Hartnell was awarded Member in the Order of Australia (AM), and subsequently the Centenary Medal, in recognition of his achievements in structuring and chairing the peak bodies for corporate regulation in Australia.”
Tony Hartnell AM is a retiring partner and co-founder of the leading law firm Atanaskovic Hartnell, the Australian corporate counsel for Parnell. Mr. Hartnell began his legal career in government, rising rapidly to Deputy Secretary, Department of Business and Consumer Affairs, and then moved to private practice as a corporate and commercial lawyer. In that time Mr. Hartnell also served on numerous governmental advisory bodies in the fields of trade, telecommunications and corporate regulation.
Mr. Hartnell said, “I joined the Board because Parnell is making a success of its entry into world markets. It has proven strengths in its chosen fields and has identified viable opportunities to build on its achievements. The Board is focused on profitable growth and will be working diligently to that end.”
Parnell (OTC: PARNF) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. Parnell is a technology and clinical science leader in dairy reproduction, marketing and growing its proprietary brands estroPLAN and GONAbreed via its dedicated sales force and digital enabler MYsynch in the USA and Australia-New Zealand, and via distributors in other markets. Parnell has a rapidly growing contract manufacturing business supplying industry majors with specialized sterile injectable products. In companion animal, Parnell markets its proprietary canine osteoarthritis brands Zydax and Glyde and is actively developing novel new products to address unmet needs.
For more information on the company and its products, please visit www.parnell.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of the U.S. Private Securities Reform Act of 1995. Words such as “may,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,” “develops,” “believes,” and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. Forward-looking statements represent management’s present judgment regarding future events and are subject to a number of risk and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding Parnell’s research and development activities, its ability to conduct clinical trials of product candidates and the results of such trials, as well as risks and uncertainties relating to litigation, government regulation, economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on third parties, and other factors, including those described in Parnell’s Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on March 31, 2017, along with its other reports filed with the SEC. In light of these assumptions, risks, and uncertainties, the results and events discussed in any forward-looking statements contained in this press release might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Parnell is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise.
# # #
For more information, contact:
Parnell Pharmaceuticals Holdings
Brad McCarthy, +61 2 9667 4411
Source: Parnell Pharmaceuticals Holdings Ltd